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Abstract
Objectives ADHD has a considerable economic impact. The aim of this study is to conduct a trial-based economic evaluation of
mindfulness-based cognitive therapy (MBCT) added to treatment as usual (TAU) versus TAU in adults with ADHD.
Methods A Dutch economic evaluation with a time horizon of 9 months was conducted from the societal perspective in the
intention-to-treat (ITT) sample. Costs were assessed with a self-report questionnaire. Outcomes were expressed in quality
adjusted life years (QALYs) and response rate. Bootstrap simulations were performed to estimate mean costs, QALYs, response
rate, incremental cost-effectiveness ratios (ICERs), and associated uncertainty. Additional sensitivity analyses were done with
imputed data, without extreme cost outliers, using the per protocol sample, and from a health care perspective.
Results In the ITT sample, societal costs were €3572 for MBCT + TAU (n = 47; 95% CI 2416 to 4995) and €3389 for TAU (n =
49; 2327 to 4763). Average QALYs were 0.542 (0.522 to 0.563) per patient for MBCT + TAU and 0.534 (0.511 to 0.556) for
TAU. In MBCT + TAU, more patients responded than in TAU (31% versus 6%; M bootstrapped difference 25%, 12 to 40%).
ICERs were €21,963 per QALY gained and €389 per responder. At a threshold of €30,000 per QALY, the probability of MBCT
being cost-effective was 51%. All sensitivity analyses showed more favorable results for MBCT + TAU.
Conclusions In most analyses, MBCT was found to be more costly and effective, particularly in terms of disease-specific
outcome, than TAU. If the threshold exceeds €30,000 per QALY and €1000 per responder, MBCT seemed cost-effective in
treating adult ADHD.
Keywords Adult ADHD .Mindfulness-based cognitive therapy . Cost-effectiveness . Health economy . Quality of life
Attention-deficit hyperactivity disorder (ADHD) is a
neurodevelopmental disorder with an estimated prevalence
of 2.5% at adult age (Simon et al. 2009). Its core symptoms
affect academic, professional, and social functioning
(Karlsdotter et al. 2016), and have a considerable personal
and economic impact.
A systematic review of Doshi et al. (2012) showed that in
the USA, the estimates of overall annual incremental (excess)
costs associated with adult ADHD ranged from $105 to 194
billion. These overall societal costs, including costs for health
care as well as productivity loss, were found to be almost three
times higher for adults than for children and adolescents with
ADHD. Workforce productivity and income loss ($87 to 138
billion) was the largest contributor to the economic burden
and accounted for 71 to 83% of the overall adult ADHD costs.
ADHD was found to be associated with an additional 22 days
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of lost role performance per year, including both absenteeism
and presenteeism (de Graaf et al. 2008). The estimates of
overall annual incremental health care costs associated with
adult ADHD ranged from $16 to 50 billion (Doshi et al.
2012). Comorbid psychiatric disorders, such as depression
and anxiety disorders (Hodgkins et al. 2011; Karlsdotter
et al. 2016), and risky behavior leading to traffic accidents
(Bernfort et al. 2008) appeared to be more prevalent among
ADHD patients, resulting in higher medical costs.
Evidently, effective interventions are needed in order to
reduce functional impairments in adults with ADHD. In par-
ticular, those that are cost-effective and thus not only increase
the health benefits but also offer value for money. Although
pharmacotherapy with stimulants has proven to be effective in
the short term (Faraone and Glatt 2010; Moriyama et al.
2013), current guidelines emphasize that drug treatment
should be part of a multimodal treatment (Kooij et al. 2010;
National Institute for Health and Care Excellence [NICE]
2018; Nederlandse Vereniging voor Psychiatrie [NVvP]
2015). Only one study conducted an economic evaluation of
pharmacotherapy in adults with ADHD (Shah et al. 2017) and
no studies to date have conducted an economic evaluation of
additional psychosocial treatment options in an adult ADHD
population.
Growing evidence suggests that a mindfulness-based inter-
vention (MBI) might be a valuable additional treatment option
for adult ADHD patients (Bachmann et al. 2016; Cairncross
and Miller 2016; Hepark et al. 2015; Househam and Solanto
2016). Considered from an economic perspective, an advan-
tage of an MBI is that it can be offered in a group format. A
recent systematic review of the literature on the economic
evaluation of third-wave CBT for the management of different
physical and mental health conditions provided some evi-
dence that mindfulness-based cognitive therapy (MBCT) is
efficient from a societal or a third-party payer perspective
(Feliu-Soler et al. 2018). However, these findings are incon-
clusive as some trials gave very positive results (Bogosian
et al. 2015; Shawyer et al. 2016), while others gave only
modest results (Kuyken et al. 2015; van Ravesteijn et al.
2013). A recent multicenter, single-blind, randomized con-
trolled trial (RCT) has demonstrated that mindfulness-based
cognitive therapy (MBCT) is effective in reducing clinician-
rated core symptoms (d = 0.41) in adults with ADHD com-
pared to treatment as usual (TAU), an effect which was main-
tained at 6-month follow-up (d = 0.43). More patients in the
MBCT + TAU group (31%) than in TAU (5%) showed a
clinical reliable improvement of ADHD symptoms (Janssen
et al. 2018). However, it is unknown to what extent these
clinical benefits in symptomatology outweigh the costs from
a societal perspective, including health care costs and costs for
productivity loss, and a health care perspective, including only
medical costs. In the Netherlands, as in other countries,
policy-makers are faced with limited healthcare budgets and
need to choose among different treatment alternatives.
Economic evaluation informs these policy-makers whether
MBCT offers value for money in adults with ADHD. Thus,
the aim of the current study is to conduct an economic evalu-
ation of MBCT in addition to treatment as usual (TAU) in
adult patients with ADHD alongside a Dutch multicenter
RCT.
Method
Participants
Adult ADHD patients (over 18 years) were referred by three
specialized outpatient clinics in the Netherlands and by self-
selection. Patients were eligible when they fulfilled the criteria
of a primary DSM-IV diagnosis of ADHD assessed with the
diagnostic interview for ADHD in adults (DIVA; Kooij 2010).
Exclusion criteria were as follows: (a) not capable of filling-
out questionnaires in Dutch, (b) depressive disorder with psy-
chotic symptoms or suicidality, (c) current manic episode, (d)
borderline or antisocial personality disorder assessed with the
screening list of the clinical interview for DSM-IV axis II
disorders (SCID-II) (First and Gibbon 2004), (e) substance
dependence, (f) autism spectrum disorder, (g) tic disorder with
vocal tics, (h) learning difficulties or other cognitive impair-
ments, and (i) former participation in MBCT or other MBI
course or workshop (> 2 h). A psychiatric structured diagnos-
tic interview (MINI-Plus; Van Vliet and De Beurs 2007) was
used to assess criteria b, c, and e.
Complete data for 96 (80%) of the 120 patients (MBCT +
TAU: n = 47; TAU: n = 49) were obtained (Fig. 1). The only
difference between patients who did and patients who did not
fill-out the questionnaires at T1, T2, and/or T3 is that non-
completers were younger (M = 33, SD = 6.5) than completers
(M = 41, SD = 10.8, p < .001). Baseline characteristics be-
tween the MBCT + TAU and TAU are summarized in
Table 1. Patients in MBCT + TAU were more likely to work
as an entrepreneur than in TAU. No significant differences
were found in health care costs in the preceding 3 months
(at T0), M bootstrapped difference is €− 31 (95% CI − 294
to 235), and productivity costs, M bootstrapped difference is
€− 419 (− 1375 to 686).
Procedure
Trial Design This economic evaluation was conducted along-
side a Dutch multicenter, single-blind, parallel-group, ran-
domized controlled superiority trial on the efficacy of
MBCT + TAU (active control group) versus TAU alone (pas-
sive control group; allocation ratio 1:1) in adults with ADHD.
For more methodological details, see the published protocol
(Janssen et al. 2015). The study had a time horizon of
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9 months, from baseline till 6-months follow-up after post-
treatment (Janssen et al. 2018).
Intervention Patients in the MBCT + TAU group received, in
addition to treatment as usual, an 8-week MBCT program
(Segal et al. 2012) of 2.5 h per session and a 6-h silent day
(Janssen et al. 2015). This program was offered after the base-
line assessments. Patients were instructed to practice at home
6 days a week for about 30 min per day with audio-guided
exercises. MBCT was taught in groups with approximately
nine patients per group by four different mindfulness teachers,
who all met the advanced criteria of the internationally agreed
good practice guidelines of the UK Network for mindfulness-
based teachers (http://mindfulnessteachersuk.org.uk/pdf/
teacher-guidelines-2015.pdf). The competence levels of the
four teachers were advanced (taught nine participants),
competent (taught 21 participants), advanced beginner
(taught 22 participants) and beginner (taught six
participants) (Janssen et al. 2018) based on the mindfulness-
based interventions-teaching assessment criteria (MBI: TAC;
Crane et al. 2012).
Patients in the TAU condition received the usual treatments
for adult ADHD, consisting of pharmacotherapy and/or
psychosocial treatments such as psychoeducation and skills
training, except MBIs (Janssen et al. 2018). Patients were free
to start, continue, and stop a treatment as desired. TAU was
monitored during the study period. For a precise description of
the received TAU in the period T0 to T1, see the RCT paper
(Janssen et al. 2018).
Measures
The Trimbos/iMTA questionnaire for costs associated with
psychiatric illness (TiC-P) (Bouwmans and Hakkaart-van
Roijen 2013) was used to collect information on health care
and societal costs. Patients were asked to fill out this online
questionnaire at baseline (T0), and at 3 (T1), 6 (T2), and 9
(T3) months after baseline assessment. This self-report instru-
ment consists of information on health care consumption in-
cluding mental and general health care and medication as well
as productivity loss in paid or unpaid work due to illness. The
recall period for the TiC-P is 3 months for health care con-
sumption and 1 month for productivity loss. To equalize the
time period for health care and productivity costs, the costs for
productivity loss over 1 month were extrapolated to the re-
maining 2 months. Previous research showed that the TiC-P is
Fig. 1 CONSORT flow diagram. MBCT, mindfulness-based cognitive therapy; TAU, treatment as usual; TiC-P, Trimbos/iMTA questionnaire for costs
associated with psychiatric illness; SF-12, medical outcomes study 12-item short-form health survey; ITT, intention-to-treat
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a feasible and reliable instrument for collecting data on med-
ical consumption and productivity loss in patients with mild to
moderate mental health problems (Bouwmans et al. 2013).
For the health care costs, standardized Dutch unit costs
(Hakkaart-van Roijen et al. 2015) were used. When prices
were not available, market prices were used. Additional treat-
ment costs were €445 per person for patients who participated
in the MBCT group, based on the applied price of the
Radboudumc Center for Mindfulness. Medication costs were
retrieved from the Dutch national tariff list accessed from July
till September 2016 (Zorginstituut Nederland [ZIN] 2016).
Medication costs that could not be retrieved from this website
(e.g., vitamin pills) were excluded.
For the productivity costs, productivity loss in paid
work was calculated according to the friction cost method:
the number of hours patients were absent from their job
multiplied by the actual gross wage per hour (Hakkaart-
van Roijen et al. 2015). Only absenteeism was considered
and the cause of absence was not taken into account. The
friction period was defined as the period needed to replace
the ill worker and to restore the initial production level.
After this period, productivity costs fall back to zero.
Following the Dutch manual for costing in economic eval-
uations (Hakkaart-van Roijen et al. 2015), a friction period
of 85 days was used. Productivity loss in unpaid work was
measured by multiplying the hours others took over unpaid
labor tasks of the patient due to illness by the costs
(Hakkaart-van Roijen et al. 2015).
Dutch price indices were used to update health care and
productivity costs to the 2015 price level (Centraal Bureau
voor de Statistiek [CBS] 2016). Costs were presented in
Euros (the exchange rate with the US dollar was 1.11 in 2015).
Effectiveness was expressed in two ways: (1) with a gener-
ic measure of health benefit expressed in quality adjusted life
years (QALY = 1 year of life in optimal health), assessed with
the medical outcomes study 12-item short-form health survey
(SF-12; Ware et al. 1996), and (2) with a disease-specific
measure of treatment response based on the DSM-IV symp-
tom score of the screening version of the Conners’ adult
ADHD rating scale (CAARS-INV: SV; Adler et al. 2007).
Both outcome measures were assessed at T0, T1, T2, and
T3. The SF-12 was reported online by the patients. The SF-12
scores were converted to the SF-6D, which is a 6-dimensional
health state classification derived from a selection of SF-36
items (McHorney et al. 1993). At each time point, the six
health states of the SF-6D were converted in utility values
by assigning average preference weights derived from a gen-
eral UK population of adults (Brazier et al. 2002). From these
utility scores QALYs were calculated for each patient using
the area under the curve (AUC) method combined with the
last observation carried forward (LOCF) technique in case of
one missing utility value. In addition, difference scores in
utilities between T1/T2/T3 and baseline were calculated.
The CAARS-INVwas rated by a blinded clinician to assess
ADHD symptoms. Ratings were organized in DSM-IV symp-
tom scores and these scores were converted in binomial vari-
ables (improved/unimproved) based on the reliable change
index (RCI) of Jacobson and Truax (1991) to determine which
patients responded to the treatment between baseline and T1.
This time interval was similar to the used interval in the RCT
(Janssen et al. 2018). Patients were considered improved
when the RCI was smaller than − 1.96.
Data Analyses
Economic evaluations with generic and disease-specific effect
measures were done on complete cases, i.e., all patients who
filled-out the TiC-P and SF-12 or CAARS-INVat T1, T2, and
T3. The base case analyses were performed from the societal
perspective, including health care costs and costs for produc-
tivity loss, within the intention-to-treat (ITT) sample.
Additionally, these analyses were replicated in the per proto-
col (PP) sample, consisting of only those patients who com-
pleted the originally allocated treatment (MBCT + TAU: pa-
tients who attended ≥ 4 MBCT sessions; TAU: patients who
did not attend an MBI). Total costs were based on adding up
the health care and productivity loss costs for T1, T2, and T3,
reaching a time horizon of 9 months. The mean health care
costs per person were compared between the two groups.
Mean costs for health care and productivity loss were com-
pared between groups at T0 to check for baseline differences.
Table 1 Baseline characteristics of 96 study participants
MBCT + TAU (n = 47) TAU (n = 49)
n % n % pa
Female gender 24 51 23 47 .686
Age; M (SD) 41.3 11.4 40.7 10.2 .807b
Civil classc .639
Married/living together 24 52 30 61
Unmarried/single 14 30 14 29
Divorced 7 15 5 10
Widowed 1 2 0 0
Employment statusc .036
Student 5 11 2 4
Wage labor 18 39 23 47
Entrepreneur 10 22 2 4
Housewife/man 1 2 4 8
Unemployed 7 15 8 16
(Partially) disabled 4 9 10 20
Elderly pension 1 2 0 0
Educational levelc .123
Low 7 15 3 6
Middle 15 33 25 51
High 24 52 21 43
a Chi-square test
b Independent samples t test
c Baseline questionnaires were filled out by n = 46 participants in the
MBCT + TAU group
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Bootstrap simulations with 1000 replications were per-
formed, since cost data are generally highly skewed. Mean
costs, QALYs, and response rate per treatment arm were cal-
culated from the bootstrap replications, as well as 95% confi-
dence intervals using the percentile method. The replications
were graphed on a cost-effectiveness plane. The horizontal
axis of this plane represents the incremental effects and the
vertical axis represents the incremental costs. Each quadrant in
the plane has a different implication for decision-making. If
the majority of the cost-effectiveness pairs is located in the
northwest quadrant, this would indicate that MBCT is more
costly and less effective than TAU (MBCT is dominated).
However, if the majority of the cost-effectiveness pairs is lo-
cated in the southeast quadrant, this would indicate that
MBCT is less costly and more effective than TAU (MBCT
dominates). If the majority of the cost-effectiveness pairs is
located in the other two quadrants, the cost-effectiveness of
MBCT depends on the societal willingness to pay (WTP) for
the gain of one extra unit of effect (QALYor responder), or the
willingness to accept for a loss in effect. In this case, an incre-
mental cost-effectiveness ratio (ICER) is calculated by divid-
ing the incremental costs of MBCT by the incremental effects,
which gives an estimate of the extra costs that are needed to
gain one QALY/responder, or, if it is less costly and less ef-
fective, the savings per lost QALY/responder. A cost-
effectiveness acceptability curve (CEAC) is constructed
showing the probability that the found ICER is acceptable
for a range of monetary values that society might consider as
the maximum WTP for a gain of one extra unit of effect. For
the analyses with a generic effect measure, threshold values of
€30,000 (NICE 2013) and €80,000 (ZIN 2015) per QALY
were reported.
Secondary analyses with generic and disease-specific
effect measures were performed from a health care per-
spective, with only medical costs included. Additionally,
some sensitivity analyses for the analysis with a generic
effect measure from a societal perspective in the ITT sam-
ple were conducted to assess the robustness of the results.
At first, missing data were imputed according to LOCF
and multiple imputation (MI) techniques. For MI, five
datasets were created and these data were combined to
produce estimates of the costs and QALYs. Secondly, an
analysis without extreme cost outliers due to a physical,
not ADHD-related problem was done.
Results
Effectiveness
GenericMean difference scores in utilities based on the SF-6D
between T1 and baseline were 0.026, (− 0.008 to 0.060), for
MBCT + TAU and 0.003, (− 0.028 to 0.034), for TAU
(Fig. 2). Difference scores increased the next 3 months in both
groups. However, in the last 3 months these scores further
increased in TAU, but decreased in MBCT + TAU. Average
QALYs over the 9-month period were 0.542 per patient for
MBCT + TAU (0.522 to 0.563) and 0.534 for TAU (0.511 to
0.556), see Table 3.
Disease-Specific In MBCT + TAU, 14 (31%; 18 to 44%) pa-
tients responded to treatment and in TAU 3 (6%; 0 to 14%),
resulting in a bootstrapped difference between groups of 25%
(12 to 40%), implying that patients in MBCT + TAU
responded better to the treatment than in TAU (Table 3).
Costs
The bootstrapped total costs between MBCT + TAU (€3572;
2416 to 4995) and TAU (€3389; 2327 to 4763) were similar in
the ITT sample (Table 2). Health care costs for MBCT + TAU
were €631 (25 to 1262) higher than for TAU. This was pri-
marily due to intervention costs. Furthermore, patients in
MBCT+TAU had higher ADHD medication costs than pa-
tients in TAU. Themajority of all participants had contact with
their general practitioner, received mental health care, and
used ADHD medication. The bootstrapped productivity costs
for MBCT + TAU were €1502, (614 to 2680) and for TAU
€1989, (1074 to 3074).
Economic Evaluation
Generic Dividing the difference in bootstrapped societal costs
(€183) by the difference in bootstrapped QALYs (0.008) re-
sulted in an ICER of €21,963 per QALY gained (Table 3). The
Fig. 2 Difference scores in mean utilities between T1, T2, T3, and
baseline on the SF-6D for MBCT + TAU and TAU. MBCT,
mindfulness-based cognitive therapy; TAU, treatment as usual
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cost-effectiveness plane (Fig. 3) revealed that the cost-
effective pairs were located in all quadrants. Most pairs
(36%) were located in the north-east quadrant, where MBCT
is more effective but also more costly than TAU. The CEAC
indicated that the probability of MBCT being cost-effective is
51 and 60% if society is willing to pay €30,000 and €80,000
for one gained QALY, respectively (Fig. 4). Additional PP
analysis showed that MBCT + TAUwas €261 less costly than
TAU and resulted in a QALY gain of 0.011, implying that
MBCT dominated TAU.
Disease-Specific Dividing the difference in bootstrapped soci-
etal costs (€98) by the difference in the bootstrapped response
rate (25%) resulted in an ICER of €389 per responder gained
(Table 3). The CEAC indicated that if the societal WTP is
below €1000, the probability of MBCT being cost-effective
is 46%, whereas this probability increased to ≥ 88% if the
societal WTP is ≥ €5000 (Fig. 5). Additional PP analysis
showed that MBCT was €238 less costly than TAU with a
responder gain of 24%, resulting in MBCT dominating TAU.
Secondary Analyses
Health Care Perspective
Generic ITT analysis showed that MBCT + TAU was €631
more costly than TAU and resulted in a QALY gain of 0.008
and an ICER of €75,581. The ICER dropped to €50,390 in the
PP analysis. MBCT + TAU stayed €581 more costly than
TAU and resulted in a slightly higher QALY gain of 0.012.
Disease-Specific ITT analysis demonstrated a difference in
bootstrapped health care costs of €600 with a responder
gain of 25%, implying that MBCT is more effective but
also more costly than TAU. The corresponding ICER was
€2405 (Table 3). PP analysis showed a comparable result.
Sensitivity Analyses
Replication of the base case analyses with a generic effect
measure with imputation based on LOCF showed that
Table 2 Total and bootstrapped mean costs (in Euros) for (sub) totals per condition for complete cases in the ITT sample over 9 months
MBCT + TAU (n = 47) TAU (n = 49) Incremental costs 95% CI
% of patients M costs per person % of patients M costs per person
Health care costsa
Primary careb 85 128 76 100 27 − 24, 82
Hospital carec 30 223 33 122 101 − 50, 310
Paramedical cared 57 226 53 170 56 − 77, 191
Mental healthcaree 77 773 67 770 3 − 403, 416
Occupational health caref 11 22 20 38 − 16 − 51, 20
Alternative healersg 9 46 10 32 14 − 41, 72
ADHD medication 74 122 61 71 51* 2, 102
Other medication 46 27 57 72 − 44 − 94, 2
MBCT 98 436 0 0
Bootstrapped subtotal health care costs 1997 1366 631* 25, 1262
Costs of lost productivitya
Absent from paid work 1162 1628 − 466 − 1945, 1103
Replacement of unpaid work 335 386 − 51 − 386, 276
Bootstrapped subtotal productivity loss 1502 1989 − 487 − 1926, 1071
Bootstrapped total costs 3572 3389 183 − 1635, 2008
a The means of the subcategories are based on individual bootstrap analyses and therefore do not sum up to the subtotals
b Contact with general practitioner
c Outpatient contact with medical specialist, day treatment and inpatient treatment for medical, psychiatric, residential, and rehabilitation care, emergency
treatment
d Contact with physiotherapist, occupational therapist, speech therapist, dietician, social worker, home caregiver
e Contact with psychologist, psychiatrist, psychotherapist, visits within the mental health care, addiction treatment, support group
f Contact with company physician
g Contact with homeopath, acupuncturist
*Statistically significant difference for p < .05
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MBCT + TAU was €469 less costly than TAU and yield-
ing 0.001 more QALYs, resulting in MBCT dominating
TAU. Replication of the analyses with imputed data based
on MI showed a difference in bootstrapped costs of €109
with a difference in bootstrapped QALYs of 0.004,
resulting in a slightly higher ICER of €28,632. Analysis
without extreme cost outliers (MBCT + TAU: n = 2, can-
cer and arthrosis; TAU: n = 1, broken foot, bruised ankle
and tailbone) demonstrated that MBCT + TAU was €227
less costly combined with a QALY gain of 0.008,
resulting in MBCT dominating TAU.
Discussion
This study showed that societal costs and effects expressed in
a generic measure were slightly higher for MBCT + TAU
compared to TAU, resulting in an ICER of €21,963 per
QALY. Replications of this analysis in the treatment adherent
sample and the majority of the sensitivity analyses, revealed a
more straightforward scenario in which MBCT dominated
TAU. When the effects were expressed in a disease-specific
measure, patients in MBCT + TAU responded better to the
treatment than in TAU, resulting in an ICER of €389 per
responder in the ITT sample and in MBCT dominating TAU
in the PP sample.
When observing the costs for health care and productivity
loss separately, health care costs appeared to be higher for
MBCT + TAU than for TAU while costs for lost productivity
were not statistically significantly different. Nevertheless, the
difference between groups in lost productivity costs was quite
large, favoring MBCT + TAU. Apparently, productivity costs
had an equalizing effect on the cost differences between
groups, resulting in substantially higher ICERs from a health
care perspective in comparison to the societal perspective.
An interesting finding was the cost difference between
groups for ADHD medication, with higher costs in the
MBCT group. This cost difference increased over time.
However, the percentages of patients on ADHD drugs
increased in both groups over time (MBCT + TAU, 70
to 74%; TAU, 57 to 61%). Perhaps, participation in
MBCT improved general medication adherence due to
reasons such as a greater awareness of impairments and
decreased forgetfulness.
Limitations and Future Research
Methodological strengths of the study are the use of an ecolog-
ically valid designwhich stayed close to the daily clinical practice
of adult ADHD (Janssen et al. 2018), the use of the validated
generic measure SF-12 to calculate QALYs, the combination of
generic and disease-specific analyses which addresses the specif-
ic impairments associated with ADHD, and the inclusion ofTa
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productivity costs next to health care costs. The inclusion of
productivity costs is highly relevant since previous research
showed that ADHD had a significant impact in the workplace
(Doshi et al. 2012; Hodgkins et al. 2011).
A limitation of this study is that only productivity costs for
absenteeism and not for presenteeism were included in the
analyses. Previous studies showed that the majority of produc-
tivity loss in adult ADHD is associated with reduced efficien-
cy rather than sickness absence (Kessler et al. 2005, 2009).
However, costs for productivity loss emerging from
presenteeism were not included, because of methodological
difficulties in measuring and valuing efficiency loss
(Bouwmans et al. 2013). It is likely that this choice led to an
underestimation of the cost-effectiveness and resulted in more
conservative findings, since there is evidence that MBCT
improves the efficiency of attentional functions (Malinowski
2013). A second limitation is that the data was exclusively
based on self-report, which might have underestimated med-
ication costs (Van den Brink et al. 2004). Although research
demonstrated that the TiC-P is a reliable alternative for
collecting data on resource use compared to data from regis-
tries (Bouwmans et al. 2013), this specific patient group per-
haps had difficulty with recalling medical consumption and
productivity loss due to forgetfulness. Another limitation is
the amount of missing data of 20%, which was handled with
the sensitivity analyses based on LOCF and MI. Finally, al-
though the difference in lost productivity costs at baseline was
not significant, this difference was quite large. No adjustment
was made for this imbalance, because this difference seemed
random and therefore not predictive for costs during follow-
Fig. 4 Cost-effectiveness
acceptability curves for costs per
gained QALY. The curves
indicate the probability (y-axis) of
MBCT + TAU being cost-
effective compared to TAU, given
the threshold value (x-axis) for a
QALY. QALY, quality adjusted
life years; ICER, incremental
cost-effectiveness ratio
Fig. 3 Cost-effectiveness plane
showing 1000 bootstrap
replications of costs (in Euros)
and effects (QALY) for MBCT +
TAU and TAU from a societal
perspective in the ITT-sample.
QALY, quality adjusted life years
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up, which is an important assumptionwhen adjusting for base-
line imbalances (Van Asselt et al. 2009).
In accordance with the Dutch guideline (Hakkaart-van
Roijen et al. 2015), the friction cost method was used to esti-
mate productivity loss in paid work. In each arm, one partic-
ipant had been absent from work longer than the friction pe-
riod. These participants were absent from work during the
period between T0 and T2. Hence, in the human capital ap-
proach, the productivity costs for these participants were sim-
ilar. This implies that by using the human capital approach, the
total costs in each arm would increase, but the incremental
costs would remain the same. Hence, use of the human capital
approach would not impact the ICERs and conclusion of our
study.
There is no (inter)national consensus regarding an accept-
able cost-effectiveness threshold for health technologies. In
the Netherlands, it is suggested that this value depends on
the burden of disease with a ceiling of €80,000 per QALY in
the case of maximum burden (ZIN 2015). The exact burden of
disease for adult ADHD is unclear, but there is some empirical
information about the burden over patients and society. Garcia
et al. (2012) found an association between ADHD severity
and negative life events in adults and Hinnenthal et al.
(2005) found that the economic burden of adult ADHD was
less than depression or diabetes, but greater than seasonal
allergy. The National Institute for Clinical Excellence (NICE
2013) in the UK stated a threshold value of £20,000 to
£30,000 (approximately €22,000 to €34,000) and North
American studies usually use $50,000 or $100,000 (approxi-
mately €42,000 to €84,000) (Rudmik and Drummond 2013).
When applying €30,000 as a threshold, the probability of
MBCT being cost-effective is 51% (ITT) and 70% (PP) for
the societal perspective.
The economic evaluation with a disease-specific effect
measure (i.e., cost-effectiveness analysis) requires another
threshold value than the economic evaluation with a generic
effect measure (i.e., cost-utility analysis). By presenting the
estimated ICERs together with the corresponding probabilities
for a range of threshold values, decision makers were provid-
ed relevant information to make cost-effectiveness choices
depending on their WTP for a responder gained. Whether
these ICERs are acceptable depends for example on the con-
solidation of the treatment effects over time. A recent RCT
showed that the improvements in ADHD symptoms were
maintained until 6-month follow-up (Janssen et al. 2018),
which is promising. Additionally, it is unclear whether the
results of our trial-based economic evaluation are transferable
to other countries. Treatment as usual and associated resource
use may differ between countries, and also the effect of
MBCT might depend on cultural aspects. Readers should
carefully consider whether they expect our results to apply
to their setting. Checklists exists to do this in a formal manner
(Welte et al. 2004).
The finding that MBCT is especially cost-effective in pa-
tients who adhered to the treatment, implies that it is important
to search for effective ways to increase the adherence, for
instance by sending reminders for training sessions and active-
ly contacting participants in case of no shows. A recent pilot
study gave insight in perceived facilitators and barriers during
MBCTwhich can, in some cases, be taken into account, such
as offering a proper amount of directiveness by the teacher and
stimulating helpful coping strategies (Janssen et al. 2017).
Future research might consider combining self-report with
less subjective data sources such as patient records showing
the medical health care history registered by a health care
provider. A second recommendation is to make use of a time
Fig. 5 Cost-effectiveness
acceptability curves for costs per
gained responder. The curves
indicate the probability (y-axis) of
MBCT + TAU being cost-
effective compared to TAU, given
the threshold value (x-axis) for a
responder. QALY, quality
adjusted life years; ICER,
incremental cost-effectiveness
ratio
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horizon longer than 9 months to improve the accuracy of the
estimates. Furthermore, subgroup analyses are suggested on
clinically relevant constructs to explore which ADHD patients
benefit most of MBCT, for instance, patients with and without
psychiatric comorbidity, since previous research showed that a
substantial proportion of the total costs was related to the
treatment of comorbidity such as depression (Birnbaum
et al. 2005). A last recommendation is to develop a more
responsive utility measure, since the SF-12 might be too ge-
neric to assess clinically relevant changes in ADHD patients.
In this study, this restriction was handled by also expressing
effectiveness in a disease-specific measure of treatment
response.
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